IO Biotech has entered into a collaborative agreement with Merck & Co (NYSE: MRK), known as MSD outside the US and Canada, through a subsidiary, to clinically evaluate IO102 in combination with Keytruda (pembrolizumab) in patients with non-small cell lung cancer, the private Danish company disclosed on Monday.
IO102, IO Biotech's lead candidate, is an IDO-derived immune modulating therapy with dual mode of action killing both cancer and immune-suppressive cells.
The company's other IDO-derived immune modulating therapies have previously shown a favourable safety profile, as well as signs of promising anti-tumour activity in a first-in-man trial of heavily pre-treated patients with NSCLC.
The terms of the collaboration state that IO Biotech will conduct an international Phase 1/2 study to evaluate the combination of IO102 with MSD's anti-PD-1 therapy. The study will involve an open-label, randomised, Phase 1/2 trial investigating the safety and efficacy of IO1012 in combination with pembrolizumab, with or without chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer.
IO Biotech will sponsor the clinical trials, while MSD will provide the trial with Keytruda. The two companies will share the rights to the study results, but IO Biotech will maintain global commercial rights to IO102.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib